Axsome Therapeutics, Inc. (AXSM) DCF Valuation

Axsome Therapeutics, Inc. (AXSM) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Axsome Therapeutics, Inc. (AXSM) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Axsome Therapeutics, Inc.? Our AXSM DCF Calculator integrates real-world data with comprehensive customization features, allowing you to refine your forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 50.0 270.6 338.3 422.8 528.5 660.6 825.8
Revenue Growth, % 0 0 0 0 440.8 25 25 25 25 25
EBITDA -67.2 -99.1 -123.6 -174.2 -225.0 79.1 98.8 123.5 154.4 193.0
EBITDA, % 100 100 100 -348.21 -83.15 23.37 23.37 23.37 23.37 23.37
Depreciation .0 .1 1.2 5.6 6.8 212.2 265.2 331.5 414.4 518.0
Depreciation, % 100 100 100 11.12 2.53 62.73 62.73 62.73 62.73 62.73
EBIT -67.2 -99.1 -124.7 -179.8 -231.8 77.3 96.7 120.8 151.1 188.8
EBIT, % 100 100 100 -359.33 -85.67 22.87 22.87 22.87 22.87 22.87
Total Cash 220.0 183.9 86.5 200.8 386.2 338.3 422.8 528.5 660.6 825.8
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 37.7 94.8
Account Receivables, % 100 100 100 75.34 35.04
Inventories .0 .0 .0 4.3 15.1 212.6 265.7 332.1 415.2 519.0
Inventories, % 100 100 100 8.63 5.59 62.85 62.85 62.85 62.85 62.85
Accounts Payable 10.9 13.5 13.1 38.6 40.7 265.3 331.6 414.6 518.2 647.7
Accounts Payable, % 100 100 100 77.15 15.03 78.44 78.44 78.44 78.44 78.44
Capital Expenditure .0 .0 -.3 -.7 -.6 -1.1 -1.4 -1.7 -2.1 -2.7
Capital Expenditure, % 100 100 100 -1.4 -0.21508 -0.32365 -0.32365 -0.32365 -0.32365 -0.32365
Tax Rate, % -0.40289 -0.40289 -0.40289 -0.40289 -0.40289 -0.40289 -0.40289 -0.40289 -0.40289 -0.40289
EBITAT -68.6 -101.5 -129.0 -190.0 -232.8 77.3 96.7 120.8 151.1 188.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -57.6 -98.9 -128.6 -201.7 -292.4 132.8 304.3 380.4 475.5 594.4
WACC, % 10.09 10.09 10.09 10.09 10.09 10.09 10.09 10.09 10.09 10.09
PV UFCF
SUM PV UFCF 1,348.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 606
Terminal Value 7,492
Present Terminal Value 4,632
Enterprise Value 5,980
Net Debt -200
Equity Value 6,180
Diluted Shares Outstanding, MM 45
Equity Value Per Share 136.05

What You Will Receive

  • Comprehensive Financial Model: Axsome Therapeutics’ actual data allows for accurate DCF valuation.
  • Full Forecasting Flexibility: Modify revenue growth, profit margins, WACC, and other essential metrics.
  • Real-Time Calculations: Automatic updates provide immediate results as you make adjustments.
  • Professional-Grade Template: A polished Excel file crafted for top-tier valuation.
  • Customizable and Versatile: Designed for adaptability, enabling repeated use for in-depth forecasts.

Key Features

  • Customizable Financial Metrics: Adjust essential factors such as revenue projections, R&D spending, and operational costs.
  • Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional financial metrics in real-time.
  • High-Precision Accuracy: Leverages Axsome Therapeutics' actual financial data for credible valuation results.
  • Effortless Scenario Analysis: Evaluate various assumptions and analyze results with ease.
  • Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Axsome Therapeutics data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Axsome Therapeutics’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Axsome Therapeutics Calculator?

  • Accuracy: Utilizes real Axsome Therapeutics financial data for precise calculations.
  • Flexibility: Tailored for users to easily adjust and test various inputs.
  • Time-Saving: Eliminate the need to create a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
  • User-Friendly: Intuitive interface suitable for users with any level of financial modeling experience.

Who Should Use Axsome Therapeutics, Inc. (AXSM)?

  • Investors: Gain insights into innovative therapies and make informed investment decisions.
  • Healthcare Analysts: Utilize comprehensive research and data to evaluate the company's pipeline and market potential.
  • Pharmaceutical Consultants: Tailor reports and presentations on Axsome’s developments for clients in the biopharmaceutical sector.
  • Medicine Enthusiasts: Explore advancements in treatment options and their implications for patient care.
  • Educators and Students: Incorporate real-world case studies of Axsome Therapeutics into healthcare and business curricula.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Axsome Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Axsome Therapeutics, Inc. (AXSM).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.